Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: The Breast Recurrence In Tissues Study (BRITS)

Breast Cancer Research

Volumn 12, Issue 6, 2010, Pages

  Thompson, Alastair M ^a,b   Jordan, Lee B ^a   Quinlan, Philip ^a   Anderson, Elizabeth ^c   Skene, Anthony ^d   Dewar, John A ^a   Purdie, Colin A ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c ASTRAZENECA   (United Kingdom)

^d ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER; HER2 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER TISSUE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIMARY TUMOR; PROSPECTIVE STUDY; TISSUE MICROARRAY; TREATMENT PLANNING; TUMOR BIOPSY; WILCOXON SIGNED RANKS TEST; BREAST TUMOR; CLINICAL TRIAL; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; NONPARAMETRIC TEST; PATHOLOGY; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSTMENOPAUSE; PROSPECTIVE STUDIES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 78049459908     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2771     Document Type: Article

References (34)

1. Stebbing J, Slater S, Slevin M. Breast cancer (metastatic). Clin Evid (Online) 2007, pii:0811.
2. Dawood S, Broglio K, Gonzalez-Angulo AM, Buzdar AU, Hortobagyi GN, Giordano SH. Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer. J Clin Oncol 2008, 26:4891-4898. 10.1200/JCO.2007.14.1168, 2736998, 18725649.
3. Amir E, Clemons M. Should a biopsy be recommended to confirm metastatic disease in women with breast cancer?. Lancet Oncol 2009, 10:933-935. 10.1016/S1470-2045(09)70295-5, 19796747.
4. Sharma A, Crook T, Thompson A, Palmieri C. Surgical oncology: why biopsying metastatic breast cancer should be routine. Nat Rev Clin Oncol 2010, 7:72-74. 10.1038/nrclinonc.2009.222, 20118974.
5. Brennan MJ, Donegan WL, Appleby DE. The variability of estrogen receptors in metastatic breast cancer. Am J Surg 1979, 137:260-262. 10.1016/0002-9610(79)90159-4, 426187.
6. Kuukasjärvi T, Kononen J, Helin H, Holli K, Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 1996, 14:2584-2589.
7. Feng Y, Sun B, Li X, Zhang L, Niu Y, Xiao C, Ning L, fang Z, Wang Y, Zhang L, Cheng J, Zhang W, Hao X. Differentially expressed genes between primary cancer and paired lymph node metastases predict clinical outcome of node-positive breast cancer patients. Breast Cancer Res Treat 2007, 103:319-329. 10.1007/s10549-006-9385-7, 17123152.
8. Wu JM, Fackler MJ, Halushka MK, Molavi DW, Taylor ME, Teo WW, Griffin C, Fetting J, Davidson NE, De Marzo AM, Hicks JL, Chitale D, Ladanyi M, Sukumar S, Argani P. Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 2008, 14:1938-1946. 10.1158/1078-0432.CCR-07-4082, 18381931.
9. Kreike B, Halfwerk H, Armstrong N, Bult P, Foekens JA, Veltkamp SC, Nuyten DS, Bartelink H, van de Vijver MJ. Local recurrence after breast conserving therapy in relation to gene expression patterns in a large series of patients. Clin Cancer Res 2009, 15:4181-4190. 10.1158/1078-0432.CCR-08-2644, 19470741.
10. Price K, Goldhirsch A, Cavalla F, Simoncini E, Castiglione M, Rudenstam CM, Collins J, Lindtner J, Gelber RD. Sequential estrogen receptor determinations from primary breast cancer and at relapse: prognostic and therapeutic relevance. Ann Oncol 1992, 3:733-740.
11. Li BD, Byskosh A, Molteni A, Duda RB. Estrogen and progesterone receptor concordance between primary and recurrent breast cancer. J Surg Oncol 1994, 57:71-77. 10.1002/jso.2930570202, 7934066.
12. Wang B, Guan ZZ, Liu DG, Lin TY, Zhang L, Xia ZJ, Teng XY. Discordance of estrogen receptor, progestin receptor and HER-2 statuses between primary and metastatic focuses of breast cancer. Ai Zheng 2004, 23:1710-1713.
13. Broom RJ, Tang PA, Simmons C, Bordeleau L, Mulligan AM, O'Malley FP, Miller N, Andrulis IL, Brenner DM, Clemons MJ. Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer. Anticancer Res 2009, 29:1557-1562.
14. Sari E, Guler G, Hayran M, Gullu I, Altundag K, Ozisik Y. Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer. Med Oncol 2010,
15. Amir E, Ooi WS, Simmons C, Kahn H, Christakis M, Popovic S, Kalina M, Chesney A, Singh G, Clemons M. Discordance between receptor status in primary and metastatic breast cancer: an exploratory study of bone marrow biopsies. Clin Oncol (R Coll Radiol) 2008, 20:763-768.
16. Amir E, Freedman O, Simmons C, Miller N, Geddie W, DeBorja A, Maung H, Gianfelice D, Murphy K, Clemons M. Biopsy confirmation of metastatic breast cancer: interim results of a prospective biopsy study. Breast Cancer Res 2009, 11(Suppl 1):P31.
17. Simmons C, Miller N, Geddie W, Gianfelice D, Oldfield M, Dranitsaris G, Clemons MJ. Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?. Ann Oncol 2009, 20:1499-1504. 10.1093/annonc/mdp028, 2731014, 19299408.
18. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999, 17:1474-1481.
19. Detre S, Saclani JG, Dowsett M. A 'quickscore' method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995, 48:876-878. 10.1136/jcp.48.9.876, 502883, 7490328.
20. Purdie CA, Jordan JB, McCullouch JB, Edwards SL, Cunningham J, Walsh M, Grant A, Pratt N, Thompson AM. HER2 assessment on core biopsy specimens using monoclonal antibody CB11 accurately determines HER2 status in breast carcinoma. Histopathology 2010, 56:702-707. 10.1111/j.1365-2559.2010.03533.x, 20546335.
21. Camp RL, Neumeister V, Rimm DL. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers. J Clin Oncol 2008, 26:5630-5637. 10.1200/JCO.2008.17.3567, 18936473.
22. Rhodes A, Jasani B, Balaton AJ, Barnes DM, Miller KD. Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value and mammographic screening. J Clin Pathol 2000, 53:688-696. 10.1136/jcp.53.9.688, 1731243, 11041059.
23. Gown AM. Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 2008, 21 Suppl 2:S8-S15. 10.1038/modpathol.2008.34, 18437174.
24. Mann GB, Fahey VD, Feleppa F, Buchanan MR. Reliance on hormone receptor assays of surgical specimens may compromise outcome in patients with breast cancer. J Clin Oncol 2005, 23:5148-5154. 10.1200/JCO.2005.02.076, 16051956.
25. Zhang D, Salto-Tellez M, Putti TC, Do E, Koay ES. Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol 2003, 16:79-84. 10.1097/01.MP.0000047307.96344.93, 12527717.
26. Graham AD, Faratian D, Rae F, Thomas JS. Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization. Histopathology 2008, 52:847-855. 10.1111/j.1365-2559.2008.03047.x, 18494613.
27. Liedke C, Broglio K, Moulder S, Hsu L, Kau SW, Symmans WF, Albarracin C, Meric Bernstam F, Woodward W, Theriault RL, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent cancer. Ann Oncol 2009, 20:1953-1958. 10.1093/annonc/mdp263, 19596702.
28. Carlsson J, Nordgren H, Sjostrom J, Wester K, Vellman K, Bengtsson NO, Ostenstad B, Lundqvist H, Blomqvist C. HER2 expression in breast cancer primary tumours and corresponding metastases. Original data and literature review. Brit J Cancer 2004, 90:2344-2348. 2409528, 15150568.
29. Tapia C, Savic S, Wanger U, Schonegg R, Novotny H, Grilli B, Herzog M, Barascud AD, Slobec I, Cathomas G, Terracciano L, Feichter G, Bubendorf L. HER2 gene status in primary breast cancers and matched distant metastases. Breast Cancer Res 2007, 9:R31. 10.1186/bcr1676, 1929093, 17511881.
30. Gong Y, Booser DJ, Sneige N. Comparison of HER-2 status determined by fluorescence in situ hybridisation in primary and metastatic breast carcinoma. Cancer 2005, 103:1763-1769. 10.1002/cncr.20987, 15786420.
31. Kamby C, Rasmussen BB, Kristensen B. Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence. Br J Cancer 1989, 60:252-257. 2247047, 2765376.
32. Johnston SR, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR, Dowsett M. Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 1995, 55:3331-3338.
33. Koboyashi H, Sugihara K, Uetake H, Higuchi T, Yasuno M, Enomoto M, Iida S, Lenz HJ, Danenberg KD, Danenberg PV. Messenger RNA expression of COX-2 and angiogenic factors in primary colorectal cancer and corresponding liver metastasis. Int J Oncol 2009, 34:1147-1153.
34. Wang L, Ma J, Liu F, Yu Q, Chu G, Perkins AC, Li Y. Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance. Gynecol Oncol 2007, 105:695-702. 10.1016/j.ygyno.2007.02.004, 17368732.